Gerresheimer (ETR:GXI) has been given a €72.00 ($83.72) target price by research analysts at JPMorgan Chase & Co. in a note issued to investors on Tuesday. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s target price would indicate a potential upside of 7.38% from the stock’s current price.
GXI has been the topic of a number of other research reports. Commerzbank set a €68.00 ($79.07) price target on Gerresheimer and gave the company a “neutral” rating in a research report on Wednesday, August 29th. Credit Suisse Group set a €88.00 ($102.33) price target on Gerresheimer and gave the company a “buy” rating in a research report on Friday, September 28th. Hauck & Aufhaeuser set a €52.50 ($61.05) price target on Gerresheimer and gave the company a “sell” rating in a research report on Monday, July 16th. Berenberg Bank set a €85.00 ($98.84) price objective on Gerresheimer and gave the company a “buy” rating in a report on Friday, July 27th. Finally, Goldman Sachs Group set a €70.00 ($81.40) price objective on Gerresheimer and gave the company a “neutral” rating in a report on Monday, June 18th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of €72.33 ($84.11).
GXI stock traded down €1.45 ($1.69) during mid-day trading on Tuesday, reaching €67.05 ($77.97). The company had a trading volume of 102,560 shares, compared to its average volume of 140,925. Gerresheimer has a fifty-two week low of €59.97 ($69.73) and a fifty-two week high of €78.25 ($90.99).
Gerresheimer Company Profile
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Featured Article: What are the risks of holding treasury bonds?
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.